On May 16, 2018 Clovis Oncology, Inc. (NASDAQ: CLVS) reported that seven abstracts highlighting progress in the Rubraca preclinical research and clinical development program will be presented at the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place June 1-5 in Chicago (Press release, Clovis Oncology, MAY 16, 2018, View Source [SID1234526702]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstracts include additional data from the phase 3 ARIEL3 clinical trial, as well as summaries of ongoing preclinical research and multiple clinical trials in which Rubraca is being studied as monotherapy and in combination in cancer types including ovarian, bladder, prostate and breast cancers.

"Rubraca has demonstrated its ability to reduce the risk of disease progression following platinum-based chemotherapy for women with advanced ovarian cancer, and our team is dedicated to fully exploring the potential of this molecule as a new treatment option for patients being treated for other cancer types where PARP inhibitors have shown encouraging results," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "We look forward to sharing updates on the progress of our clinical development program at ASCO (Free ASCO Whitepaper) 2018."

The four Clovis Oncology-sponsored abstracts accepted for presentation at the 2018 ASCO (Free ASCO Whitepaper) Annual Meeting comprise:

Abstract TPS4592 (Poster 415a) – ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).

Presenter: Petros Grivas, MD, PhD, University of Washington
Session: Genitourinary (Nonprostate) Cancer
Date/Time: Saturday, June 2, 8:00 -11:30 a.m. CT
Location: Hall A
Abstract 5537 (Poster 264) – Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.

Presenter: Carol Aghajanian, MD, Memorial Sloan Kettering Cancer Center
Session: Gynecologic Cancer
Date/Time: Monday, June 4, 1:15 -4:45 p.m. CT
Location: Hall A
Abstract 5545 (Poster 272) – Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.

Presenter: Ana Oaknin, MD, PhD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO)
Session: Gynecologic Cancer
Date/Time: Monday, June 4, 1:15 -4:45 p.m. CT
Location: Hall A
Abstract 5582 (Poster 309) – Efficacy and immune modulation of the tumor microenvironment with the combination of the PARP inhibitor rucaparib and CD122-biased agonist NKTR-214.

Presenter: Andrew Simmons, PhD, Clovis Oncology
Session: Gynecologic Cancer
Date/Time: Monday, June 4, 1:15 -4:45 p.m. CT
Location: Hall A
Additionally, three additional collaborator and investigator sponsored abstracts investigating Rubraca in metastatic breast and prostate cancers are also being presented:

Abstract TPS1112 (Poster 187a) – An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.

Presenter: Anne Patsouris, Institute of West Cancerology Paul Papin
Session: Breast Cancer – Metastatic
Date/Time: Saturday, June 2, 8:00-11:30 a.m. CT
Location: Hall A
Abstract TPS5095 (Poster 317b) – Phase II trial of rucaparib (without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH).

Presenter: Mark Christopher Markowski, MD, PhD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Session: Genitourinary (Prostate) Cancer
Date/Time: Saturday, June 2, 1:15-4:45 p.m. CT
Location: Hall A
Abstract TPS3126 (Poster 327b) – An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).

Presenter: Karim Fizazi, MD, PhD, Gustave Roussy
Session: Developmental Therapeutics—Immunotherapy
Date/Time: Monday, June 4, 8:00-11:30 a.m. CT
Location: Hall A
Clovis Oncology’s Rubraca posters will be available online at View Source as of the time they are presented at the meeting.

About Rubraca (rucaparib)

Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in ovarian cancer as well as several additional solid tumor indications. Studies open for enrollment or under consideration include ovarian, prostate, breast, gastroesophageal, pancreatic, lung and bladder cancers. Clovis holds worldwide rights for Rubraca.

In the United States, Rubraca is approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Rubraca is also approved in the United States for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca.

Rubraca is an unlicensed medical product outside of the U.S.